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Analysis of treatment success regarding oncological recurrence rate between standard and 
dose escalation focal high-intensity focused ultrasound (HIFU) of prostate cancer.  
Materials and methods 
In this analysis of our prospectively maintained HIFU (Sonablate® 500) database, 598 
patients were identified who underwent a focal HIFU (Sonablate® 500) between March 
2007 and November 2016. Follow-up occurred with 3-monthly clinic visits and PSA testing 
in the first year. Thereafter, PSA was measured 6-monthly or annually at least. Routine and 
for-cause mpMRI with biopsy for MRI-suspicion of recurrence. Treatments were delivered 
in a quadrant or hemiablation fashion depending on the gland volume as well as tumour 
volume and location. Prior to mid-2015, standard focal-HIFU was used (two HIFU blocks); 
after this date some urologists conducted dose escalation focal-HIFU (3 overlapping HIFU 
blocks). Propensity matching was used to ensure two matched groups leading to 162 cases 
for this analysis.  Treatment failure was defined by any secondary treatment (systemic 
therapy, cryotherapy, radiotherapy, prostatectomy, or further HIFU), metastasis from 
prostate cancer without further treatment, tumour recurrence with Gleason score >/=7 
(>/=3+4) on prostate biopsy without further treatment, or prostate cancer-related 
mortality. Complications and side-effects were also compared. 
Results  
Median age was 64.5 years (IQR 60-73.5) in the standard focal-HIFU group and 64.5 years 
(IQR 60-69) in the dose-escalation group. Median prostate volume was 37ml (IQR 17-103) 
in standard group and 47.5ml (IQR 19-121) in the dose-escalation group. As tumour 
volume on mpMRI and Gleason score were major matching criteria these were identical 
with 0.43ml (IQR 0.05-2.5) and Gleason 3+3=6 in 1/32 (3%), 3+4=7 in 27/32 (84%), and 
4+3=7 in 4/32 (13%). Recurrence in treated areas were found in 10/32 (31%) when 




















































































































































































































































































This exploratory study shows that dose escalation focal-HIFU may achieve higher rates of 
disease control compared to standard focal-HIFU. Further prospective comparative studies 



















































































































































































































































































Focal high intensity focused ultrasound (HIFU) has been increasingly used to treat localised 
prostate cancer [1] in order to reduce treatment margins from extending to the whole 
prostate towards areas of tumour [2]. The aim is to target areas of clinically significant 
prostate cancer accurately whilst conferring a reduction in treatment-related harms [3], 
provided patients are diagnosed, staged and selected appropriately [4].  
Recent results from our own group and others have shown good cancer control in the 
medium term, with rates of radical or systemic therapy of 10% at 5 years although further 
sessions of focal HIFU are needed in about 20-30% within the same time period [5,6,7]. 
Just as with traditional radical therapy, failure can sometimes occur, and like other surgical 
innovations and technologies, adjustments are often made to technique in order to 
optimise therapy delivery.  
A number of biological reasons might account for why the first focal HIFU is unable to treat 
all the cancer cells in the area targeted. First, the margin may miss the extent of the 
tumour. Second, heat-sink effects from vasculature can counteract the thermoablative 
effect. Third, skip lesions can occur during the treatment. Fourth, energy delivery can be 
sub-optimal. We tested the hypothesis that dose escalation of HIFU delivery by the 
application of an additional block of HIFU therapy might overcome these biological issues 
and improve disease control rates. 
Methods 
Institutional review board exemption was granted. Our programme of health technology 
assessment followed the Medical Research Council (UK) guidelines for evaluating complex 
interventions [8]; these guidelines were recently incorporated and applied to surgical 
innovation within the IDEAL framework [9]. Focal transrectal HIFU was a surgical 
innovation that commenced in 2006 in the UK and approved for clinical use by the UK’s 
National Institute for Health and Clinical Excellence (NICE) under special arrangements. 
That is, all cases had to be prospectively and consecutively entered into an academic 
registry, discussed in a multidisciplinary meeting and given written information on the 


















































































































































































































































































term outcomes following whole-gland and focal HIFU from this registry [10]. Between 
1st/January/2006 and 31st/December/2015, 625 consecutive patients underwent primary 
focal HIFU for non-metastatic prostate cancer (Sonablate®500, Sonacare Inc., USA) within 
9 centres. Focal HIFU treatment was offered to patients diagnosed with non-metastatic 
prostate cancer with Gleason 6 through 9, stage T1c-T3bN0M0 and PSA of </=20ng/ml. 
Gleason 6 required a minimum of 3mm of disease. Disease was localised using mpMRI, 
combined with targeted and systematic biopsies, or transperineal mapping biopsies. 
Intermediate and high-risk cases also underwent a radioisotope bone-scan and/or cross-
sectional CT to rule-out distant metastases dependent on local guidelines at each hospital. 
Treatments were delivered in a quadrant or hemiablation fashion, or for very small lesions 
a focal with approximate 3mm margin (so-called ultrafocal), depending on the gland 
volume as well as tumour volume and location. Index lesion ablation alone was conducted 
in patients with multifocal disease provided untreated areas harboured no more than 
3mm of Gleason 6 on systematic or template mapping biopsies. All men were advised to 
undergo 3 to 6 monthly serum PSA testing. An mpMRI was routinely performed regardless 
of PSA kinetics at 1 year and approximately 1-2 yearly thereafter. Two rises in PSA after the 
nadir level was achieved, without predefining the level of rise, was investigated with a 
prostate biopsy, or mpMRI followed by biopsy if the mpMRI was suspicious. We have 
previously reported on the high negative predictive value of mpMRI in the post-focal HIFU 
setting for clinically significant prostate cancer [11]. Clinically significant cancer on biopsy 
of untreated areas was defined as ‘out-of-field’ progression. 
Further focal HIFU was offered when either, a) clinically significant cancer on biopsy 
occurred in-field or out-of-field and where the mpMRI staging indicated that the disease 
was still localised or, b) when the mpMRI demonstrated a clear recurrence (mpMRI Likert 
score 5) in-field associated with a rising PSA. Other considerations for further focal HIFU 
were the absence of intra-prostatic calcification or difficult disease location such as apical 
disease overlapping the external urinary sphincter. Patients were also routinely offered the 
option of radical prostatectomy or radical radiotherapy. All data was audited and quality 


















































































































































































































































































Primary outcome for the validation of this dose escalation strategy was based on a 
composite endpoint of failure-free survival (FFS) with failure defined as residual untreated 
Gleason 3+4=7 or more cancer on post-treatment biopsy, local salvage therapy (surgery or 
radiotherapy), systemic therapy, prostate cancer metastases or prostate cancer-specific 
mortality.  
HIFU protocol 
Treatment planning took place using a 4cm focal length probe for anterior areas of 
treatment and a 3cm probe for posterior areas. When ablating tissue with HIFU, energy is 
delivered in repeated three-dimensional focal points over an individual predefined area. 
Each of such an ablative block covers the tumour with a surrounding safety margin. Prior 
to mid 2015, two partially overlapping ablative blocks were applied one after the other to 
target a quadrant or for ultrafocal HIFU in which the tumour resided [Figure 1a]. Following 
this date, some urologists conducted treatment in 3 layered blocks in order to deliver 
more energy [Figure 1b]. Those ablative blocks had a bigger overlapping area covering the 
tumour compared to two blocks. The total delivered energy in Joules was not recorded 
routinely but the energy per block was delivered in a similar fashion according to visually-
estimated focal-HIFU delivery. In other words, energy changes were made to each pulse if 
necessary to derive greyscale hyper-echoic changes in the focal zone. These hyperechoic 
‘pop-corning’ effects are believed to represent steam formation. 
Statistical analysis 
Variables with skewed distribution are presented as medians with interquartile ranges 
(IQR) and categorical variables as absolute numbers with percentages. Cases were paired 
with “MatchIt” package. For the purposes of this analysis, information was available on 
162 cases in whom standard focal-HIFU or dose-escalation focal-HIFU was carried out.  
Cases were matched for Gleason score according to biopsies prior to treatment and 
tumour volume in mpMRI in which matching had to be exact. Other matching criteria, 
where the nearest concordance within the groups was acceptable, were maximum cancer 
core length in diagnostic biopsies, length of last follow-up, as well as time to failure. From 


















































































































































































































































































analysed individually. Explorative analysis of basic characteristics were performed with 
Mood‘s median test, significance level for treatment results in matched pairs was 
calculated with McNemar‘s test for paired samples with p-value set at 0.05 for statistical 
significance. Analyses were performed using the R language environment for statistical 
computing.  
Results  
Baseline HIFU demographics 
In total, 64 patients were identified and matched. Median age was 64.5 years (IQR 60-73.5) 
in the standard focal-HIFU group and 64.5 years (IQR 60-69) in the dose-escalation focal-
HIFU group. Median prostate volume was 37 ml (IQR 17-103) in standard group and 47.5 
ml (IQR 19-121) in the dose-escalation group. Median tumour volume derived from 
mpMRI was a major matching criterion and therefore in both groups identical with median 
of 0.425 ml (IQR 0.05-2.5) as was Gleason score (% of cases). [Table 1]. 
Treatment outcomes 
There were no differences in rates of urinary tract infections or cystoscopic interventions 
for necrotic tissue, strictures and bladder neck contractures (Table 2). There were no 
rectourethral fistula in these matched groups (although our previous reports have shown 
this risk to be 1 in 500). Recurrences in treated areas were found in 10/32 (31%) when 
standard focal-HIFU treatment zones were applied, and in 6/32 (19%) when dose-
escalation focal-HIFU was used (p=0.007). The time that had elapsed until treatment 
failure was proven and the length of follow-up without any proof of recurrence were 12.5 
months (IQR 12-22.75) and 23 months (IQR 13-26.75) in standard focal-HIFU group, 
respectively. For the dose-escalation focal-HIFU group, these were 11.5 months (IQR 9.5-
12.75) and 13.5 months (IQR 12-26.5), respectively [Table 2]. 
Discussion 
In summary, we have shown that dose escalating in the delivery of focal-HIFU leads to 
improved cancer control compared to standard focal-HIFU delivery without significant 


















































































































































































































































































that aims to improve cancer control whilst minimising the impact on function and adverse 
events.  
Whenever there are new treatment modalities, adjustments were made. Radical 
prostatectomy is one such example. Hugh Hampton Young developed radical 
prostatectomy back in 1904, with Millins describing in 1947 the retropubic approach and 
in 1983 Patrick Walsh the anatomic radical prostatectomy, with subsequent advances in 
laparoscopic and robotic assisted approaches. There were also several amendments made 
in other urological cancer treatments such as focal radiofrequency ablation in kidney 
tumours, until it was a standard care therapy [13].  
In the minimally-invasive treatment of prostate cancer there was a key change from whole 
to partial ablations which now often is applied to treatment of the index lesion [3]. 
Manufacturer modifications have been made to the devices with improvements in 
hardware and software. Uchida et al. recently demonstrated what the impact of these 
changes were in a large consecutive series with upgraded HIFU devices following whole-
gland HIFU [14] whilst there has also been a recent change in another device from 
Ablatherm to Focal-One with a number of additional features [12]. 
Our series points to a reduced recurrence rate after escalated energy doses with a third 
treatment block; this might be explained by several factors. First, more energy is absorbed 
by the prostate tissue leading to an improved coagulative necrosis. It is known from the 
underlying basic principles in HIFU therapy that the area in which a sufficient high 
temperature for tissue ablation is reached is restricted to a focal point. Around this limited 
area there is a rapid drop in temperature and therefore insufficient energy applied for 
tissue destruction [15]. Second, there is a possibility that during treatment areas of 
untreated tissue that are in-between delivered pulses shift in space due to swelling causing 
skip-lesions that are then not treated during subsequent pulses. Shoji et al demonstrated a 
partial shift of the prostate on the basis of local tissue swelling during HIFU of 
approximately 13% volume increase and linear shifts of up to 5.5mm [16].  
When reducing HIFU from whole gland to hemiablation still 3 ablative blocks were given 


















































































































































































































































































further reducing of the ablative areas to quadrant ablations posterior tumours were 
initially only treated with 2 blocks. Although an adequate margin was treated more 
recurrences were found compared to those earlier treated with an additional block. By 
hitting a quadrant threefold it was hypothesized to ensure high energy levels to overcome 
a heatsink effect and also the effect of skip lesions [16].  
There are limitations to this study. Although it is a matched pair analysis it nonetheless is a 
retrospective analysis with a modest sample size and there might be unknown residual 
confounders that impact on treatment delivery. Whilst a prospective randomised trial to 
assess the different techniques might be possible this may not justify the significant 
resource issues involved in delivering such a trial. Our follow-up period is short. This is a 
consequence of the recent adoption of this type of dose-escalation for focal HIFU and 
therefore the follow-up for this group and the matched paired was inevitably shorter than 
what we have previously reported for the entire focal-HIFU cohort. 
Conclusion 
This exploratory study shows that dose escalation focal-HIFU may achieve higher rates of 
disease control compared to standard focal-HIFU. Long term outcomes, ideally from 
comparative effectiveness studies, for focal HIFU in treating non-metastatic prostate 
cancer are awaited. 
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PSA – prostate specific antigen 
mpMRI – multiparametric MRI 
HIFU – high intensity focused ultrasound 
FFS – Failure-free survival 
IQR – inter-quartile range 




















































































































































































































































































Table 1. Baseline demographics 






Median/N IQR/% Median/N IQR/%  
Age at treatment (in years), 
median, (IQR) 
64.5 60 – 73.5 64.5 60 – 69 1.000 
ADT pre-treatment, N, (%) 4 13% 0 0% 0.113 
PSA pre-treatment, median, (IQR) 7.0 4.72 – 10.55 6.9 5.33 – 8.21 1.000 
Prostate volume (MRI, in ml), 
median, (range) 
37 17 – 103 47.5 19 – 121 0.058 
Tumour volume (MRI, in ml), 
median, (range) 
0.43 0.05 – 2.5  0.43 0.05 – 2.5 1.000 
      
Biopsy results pre-treatment, 
median, (IQR) 
     
  no. positive cores 4.5 3 – 7.25 4 3 – 5.25 0.127 
  total cores 15 9 – 34.5 10 6 – 17 0.012 
  MCCL (in cm) 6 3.75 – 9 5 4 – 8 0.121 
  max. percentage of core (%) 50 30 – 80 55 32.5 – 65.5 0.789 
      
Gleason score pre-treatment, 
median 
3+4  3+4   
  3+3, N, (%) 1 3% 1 3% 1.000 





















































































































































































































































































  4+3 4 13% 4 13% 1.000 
      
T-stadium pre-treatment, median T2  T2   
  T1c, N, (%) 2 6% 1 3% 1.000 
  T2 24 75% 28 88% 0.337 
  T3a 6 19% 3 9% 0.474 
Abbreviations: N, number; IQR, inter quartile range; ADT, androgen deprivation therapy; 
MRI, magnetic resonance imaging; ml, millilitres; MCCL, maximum cancer core length; cm, 
centimetre; CDC, Clavien Dindo Classification; UTI, urinary tract infection; LA, local 


















































































































































































































































































Table 2. Adverse events and cancer control outcomes 
 
  






Median/N IQR/% Median/N IQR/%  
Recurrence in treated area, N, (%) 10 31% 6 19% 0.007 
Time to recurrence (months), 
median, (IQR) 
12.5 12 – 22.75 11.5 9.5 – 
12.75 
0.515 
Follow-up without recurrence 
(months), median, (IQR) 
23 13 – 26.75 13.5 12 – 26.5 0.090 
Complications post HIFU (CDC), N, 
(%) 
     
 Grade II: UTI (in first 6 month) 2 6% 0 0% 0.492 
 Grade IIIa: cystoscopy (in LA) 1 3% 2 6% 1.000 
 Grade IIIb: bladder neck 
incisions/resections (in GA) 
0 0% 2 6% 0.492 



















































































































































































































































































Figure 1a. Standard 2 block approach to focal HIFU (Sonablate, Sonacare Inc) for the 




















































































































































































































































































Figure 1b. Dose escalation using 3 blocks of treatment layered approach to focal HIFU 
(Sonablate, Sonacare Inc) for the treatment of non-metastatic prostate cancer 
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